CSIMarket
 
Titan Pharmaceuticals Inc   (TTNP)
Other Ticker:  
 
 
Price: $8.0000 $0.22 2.828%
Day's High: $8 Week Perf: 0.00
Day's Low: $ 7.65 30 Day Perf: 47.6 %
Volume (M): 5 52 Wk High: $ 18.80
Volume (M$): $ 38 52 Wk Avg: $10.88
Open: $7.69 52 Wk Low: $0.38



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

Titan Pharmaceuticals Inc
Titan Pharmaceuticals Inc. is a biopharmaceutical company that develops innovative treatments for medical disorders. Based in South San Francisco, California, the company focuses primarily on the development of therapeutics for central nervous system (CNS) disorders and conditions. Titan Pharmaceuticals is known for its expertise in the field of long-term, continuous drug delivery, utilizing its proprietary ProNeura technology platform.

The company has successfully developed and commercialized Probuphine, an implantable buprenorphine-based treatment for opioid addiction. Probuphine is designed to provide a constant, low-level release of medication for six months, eliminating the need for daily dosing and reducing the risk of non-compliance.

In addition to opioid addiction, Titan Pharmaceuticals is actively researching and developing treatments for other CNS disorders, including Parkinson's disease and hypothyroidism. The company has ongoing collaborations with various academic institutions and pharmaceutical partners to advance its research and development pipelines.

Overall, Titan Pharmaceuticals Inc. is dedicated to developing innovative therapies with an emphasis on long-term and continuous drug delivery, aiming to improve patients' quality of life and simplify treatment regimens for various medical conditions.


   Company Address: 400 Oyster Point Blvd. South San Francisco 94080 CA
   Company Phone Number: 244-4990   Stock Exchange / Ticker: NASDAQ TTNP
   TTNP is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Titan Pharmaceuticals Regains NASDAQ Compliance and Works Towards Enhanced Financial Performance

Published Thu, Jan 25 2024 9:29 PM UTC

Titan Pharmaceuticals Regains Compliance With NASDAQ Listing Criteria and Works Toward Improved ROI
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has recently announced that it has successfully regained compliance with the minimum $1.00 bid price requirement, marking a positive development for the company. In a letter dated January 24, 2024, The Nasdaq Stock Market LLC con...

Titan Pharmaceuticals Inc

Impact of Diminishing Returns on Titan Pharmaceuticals Inc during July to September 2023

n a surprising turn of events, Titan Pharmaceuticals Inc. has reported an encouraging financial performance for the July to September 30, 2023 period. The company managed to reduce its loss per share to $-0.02, a significant improvement compared to $-0.18 from the previous year. Additionally, the income per share improved from $-0.11 to an undisclosed figure, surpassing the preceding financial reporting period.
The most notable achievement for Titan Pharmaceuticals Inc. was the substantial surge in revenue, which skyrocketed by 1727.368% to $1.74 million, compared to a meager $0.10 million in the corresponding financial period a year ago. Remarkably, the revenue also doubled sequentially by an astounding 1991.566% compared to $0.08 million in the preceding period.

Titan Pharmaceuticals Inc

Titan Pharmaceuticals Inc Shows Resilience Amidst Earnings Season Slump ? A Glance at the Second Quarter of 2023

During the past 5 trading days, Titan Pharmaceuticals Inc (TTNP) shares have experienced a significant drop of -12.26%, causing concerns among investors. This downward trend has also contributed to the company's year-to-date performance, bringing it to a disappointing -33.01%. Making matters worse, TTNP shares have reached their 52-week low.
The recent decline in Titan Pharmaceuticals Inc's stock price can be attributed to the company's disclosure of disappointing financial results for the span ending June 30, 2023. During this period, the company experienced a sharp decline in revenue, plummeting by -44.667% to a mere $0.08 million. Additionally, Titan Pharmaceuticals Inc recorded a shortfall per share at $-0.11, compared to $-0.18 in the same period the preceding year.

Titan Pharmaceuticals Inc

Titan Pharmaceuticals Inc Faces Dire Financial Period, Reporting Cumulative Net Loss of $-9 Million over Fiscal First Quarter of 2023

Titan Pharmaceuticals Inc Posts Cumulative Net Loss of $-9 Million, Sees Negative ROI of -352.82%
Titan Pharmaceuticals Inc, a biotechnology and pharmaceuticals company, has reported a cumulative net loss of $-9 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -352.82%. Unfortunately, this marks a significant deterioration in the total ranking compared to the fourth quarter of 2022, where the company's ROI was at 0, and has now dropped to 3506.
While Titan Pharmaceuticals recorded a considerable loss during this period, it's also worth noting that 739 other healthcare industry companies had a higher ROI, signifying the primarily competitive nature of the sector.






 

Titan Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com